Quantcast

Latest Zidovudine Stories

2014-06-30 11:45:29

New York University HIV and its transmission has long been associated with injecting drug use, where hypodermic syringes are used to administer illicit drugs. Now, a newly reported study by researchers affiliated with New York University's Center for Drug Use and HIV Research (CDUHR) in the journal PLOS ONE, shows that HIV infection among heterosexual non-injecting drug users (no hypodermic syringe is used; drugs are taken orally or nasally) in New York City (NYC) has now surpassed HIV...

2014-06-28 09:23:51

University of Pittsburgh Schools of the Health Sciences While bringing new drugs to market is important for increasing life expectancy in younger people with HIV, lowering the toxicity of those drugs may have an even greater health impact on all HIV patients, a University of Pittsburgh Graduate School of Public Health analysis reveals. The research, supported by the National Science Foundation (NSF) and National Institutes of Health (NIH), and published June 25 in the journal PLOS ONE,...

2014-06-24 08:32:27

OAKLAND, Calif., June 24, 2014 /PRNewswire/ -- A 15-year study found that HIV-positive individuals had a 40 percent increased risk of ischemic stroke, however stroke rates were nearly the same for HIV-positive individuals with high CD4 cell counts as for HIV-negative subjects. http://photos.prnewswire.com/prnvar/20130718/SF49717LOGO The study, published recently in AIDS, the official journal of the International AIDS Society, covered the years 1996 through 2011 and included nearly...

2014-06-12 08:28:17

Agreement is ViiV Healthcare's first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine LONDON, June 12, 2014 /PRNewswire/ -- ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland Ltd (Janssen) for the development and commercialisation of a single-tablet combining dolutegravir (Tivicay®) and Janssen's non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant®([1])). This...

2014-06-12 08:28:09

CORK, Ireland, June 12, 2014 /PRNewswire/ -- Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT(R)) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY(R)) as the sole active ingredients for the maintenance treatment of people living with Human...

2014-06-10 08:29:37

Key findings point to significant differences between treated and untreated people living with HIV RESEARCH TRIANGLE PARK, N.C., June 10, 2014 /PRNewswire/ -- ViiV Healthcare today announced new survey data that provide important insights that may help explain why HIV treatment rates remain low in the United States. Findings from the online survey, conducted by Harris Interactive on behalf of ViiV Healthcare in 2013, reveal gaps in knowledge about HIV and its treatment among diagnosed but...

2014-05-28 23:15:08

Professor Mark Wainberg from McGill University in Montreal shows that Dolutegravir rarely selects for resistance mutations and when they occur, HIV growth is impaired. Toulon, Var, France (PRWEB) May 28, 2014 Professor Mark Wainberg stated at the ISHEID that "Dolutegravir resistance is very difficult to obtain in vitro" and that this situation is unique among other antiretrovirals. A New Mechanism of Resistance Selection Actually, Dolutegravir is the last approved integrase...

2014-05-19 09:55:53

University of Pittsburgh Schools of the Health Sciences The first direct proof of a long-suspected cause of multiple HIV-related health complications was recently obtained by a team led by the University of Pittsburgh Center for Vaccine Research (CVR). The finding supports complementary therapies to antiretroviral drugs to significantly slow HIV progression. The study, which will be published in the June issue of the Journal of Clinical Investigation and is available online, found that...

2014-05-02 10:06:07

Enzyme's double-edged sword may soon be sheathed Johns Hopkins biochemists have figured out what is needed to activate and sustain the virus-fighting activity of an enzyme found in CD4+ T cells, the human immune cells infected by HIV. The discovery could launch a more effective strategy for preventing the spread of HIV in the body with drugs targeting this enzyme, they say. A summary of their work was published online on April 21 in the journal Proceedings of the National Academy of...

2014-04-30 11:01:45

The risks of birth defects in children exposed to antiretroviral drugs in utero are small when considering the clear benefit of preventing mother-to-child transmission of HIV but where there are safe and effective alternatives, it might be appropriate to avoid use by pregnant women of drugs that may be associated with elevated risks of birth defects, such as zidovudine and efavirenz, according to a study published by French researchers published in this week's PLOS Medicine. The...


Latest Zidovudine Reference Libraries

0_a4499f7c8759b5cbe79bad5eca319070
2011-01-26 14:08:59

Human immunodeficiency virus (HIV), a lentivirus, causes acquired immunodeficiency syndrome (AIDS) which is a condition in humans were the immune system begins to fail, leading to life-threatening opportunistic infections. Infection is transferred through bodily fluids where HIV is present as both free virus particles and within infected immune cells. The four most common routes of infection are unsafe sex, contaminated needles, breast milk, and transmission from an infected mother to her...

More Articles (1 articles) »
Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'